Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 564-569

  Mori, Takehiko ^a   Kato, Jun ^a   Yamane, Akiko ^a   Sakurai, Masatoshi ^a   Kohashi, Sumiko ^a   Kikuchi, Taku ^a   Ono, Yukako ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug interaction; Hematopoietic stem cell transplantation; Tacrolimus; Voriconazole

Indexed keywords

TACROLIMUS; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER THERAPY; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; GRAFT RECIPIENT;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PYRIMIDINES; TACROLIMUS; TRIAZOLES; YOUNG ADULT;

EID: 84862849999     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1057-2     Document Type: Article

References (28)

1. Dykewicz CA, Jaffe HW. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;6:670-2.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-17. (Pubitemid 34229758)
3. Kami M, Machida U, Okuzumi K, Matsumura T, Mori S, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haemato- logical malignancy. Br J Haematol. 2002;117:40-6. (Pubitemid 34304419)
4. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15. (Pubitemid 34851833)
5. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther. 2003;25:1321-81. (Pubitemid 36677282)
6. Herbrecht R, Fluckiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl. 2007;5:49-59. (Pubitemid 47187744)
7. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60. (Pubitemid 351265310)
8. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730-44. (Pubitemid 44885328)
9. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther. 2002;71:226-34. (Pubitemid 34311451)
10. Wood N, Tank K, Allan R, Fielding A. Effect of voriconazole on the pharmacokinetics of tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 22-25 September 2001 (abstract A-20). Washington DC: American Society of Microbiology; 2001.
11. Inc Pfizer. Vfend (voriconazole) package insert. New York: Pfizer Inc.; 2010.
12. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2009;44:371-4.
13. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395-402. (Pubitemid 34259773)
14. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35:509-13. (Pubitemid 40403355)
15. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-2.
16. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532-5. (Pubitemid 46595688)
17. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-11. (Pubitemid 351269158)
18. Briiggemann RJ, Blijlevens NM, Burger DM, Franke B, Troke PF, Donnelly JP. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2010;65:107-13.
19. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Int J Hematol. 2009;90:103-7.
20. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53:1793-6.
21. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57. (Pubitemid 30055093)
22. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-54. (Pubitemid 37083100)
23. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-54. (Pubitemid 38373108)
24. Onizuka M, Kunii N, Toyosaki M, Machida S, Ohgiya D, Ogawa Y, et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2010; 46:1113-7. doi:10.1038/bmt.2010.273.
25. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994;22:947-55.
26. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78: 260-77. (Pubitemid 41254111)
27. Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud- Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet. 2008;47: 779-92.
28. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol. 2003;56(Suppl 1):45-50. (Pubitemid 37491733)